Senores Pharmaceuticals Ltd Share Price

Pharmaceuticals - Indian - FormulationsNSE
₹1,090.80
-22.10-1.99% (1D)
As on 20 Nov 2026 at 15:57
As of 20 Nov 2026 at 15:57, Senores Pharmaceuticals Ltd is trading at ₹1,090.80. The 52-week range stands at ₹706.00–₹1,599.00, with a market cap of ₹5.03 thousand crore. At a P/E of 252.63 and a dividend yield of 0.00%, it is a mid-cap stock in the Pharmaceuticals sector.

SENORES Price Chart

Market Cap
₹5.03K Cr
PE Ratio
252.63
ROCE
4.07%

Senores Pharmaceuticals Ltd Performance

Senores Pharmaceuticals Ltd Fundamentals

Know More
Market Cap₹5.03K Cr
ROE2.62%
P/E Ratio (TTM)252.63
EPS (TTM)₹4.32
P/B Ratio6.62
Dividend Yield0.00%
Industry P/E91.72
Book Value₹164.73
Debt to Equity0.15
Face Value₹10

Senores Pharmaceuticals Ltd Shareholding Pattern

Know More
Promoter45.8%
Foreign Institutions6%
Mutual Funds7.4%
Domestic Institutions3.5%
Public37.3%

Senores Pharmaceuticals Ltd Financial Statements

Know More
No data for this view.

Senores Pharmaceuticals Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' dated December 26, 2017, issued by the office of Central Registration Centre. Thereafter, the name was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company dated September 4, 2023. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries. In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022. The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024. The Company launched the IPO of 14,887,723 Equity Shares of face value Rs 10 each, by raising money aggregating to Rs 582.11 Crore, comprising a fresh issue of 12,787,723 equity shares amounting to Rs 500 Crore and the offer for sale of 2,100,000 equity shares amounting to Rs 82.11 Cr in December, 2024. The Company has commenced manufacturing activities at its greenfield API plant located in Gujarat in FY 2025. In FY 2025-26, the Company acquired a 75% stake in Apnar Pharma Private Limited, including its USFDA-approved facility in Jambusar, Gujarat in 2026. Further, the Company acquired a 51% membership interest in Zoraya Pharmaceuticals LLC, a US based entity through Senores Pharmaceuticals Inc., the Company's wholly owned subsidiary in November 2025.

Parent Organisation—
Founded2017
Managing DirectorSWAPNIL JATINBHAI SHAH
NSE SymbolSENORES

Senores Pharmaceuticals Ltd Resistance and Support levels

R31,151.97R21,134.32R11,123.42S11,088.12S21,077.22S31,059.571,090.80

Senores Pharmaceuticals Ltd Technicals

Current Price
₹1,090.80 ₹22.10 (-1.99%)
Bearish
12
Bullish
0
  • 20 Day7.8%
  • 50 Day13.1%
  • 100 Day13.6%
  • 200 Day6.0%

Senores Pharmaceuticals Ltd Latest News

View More
29 OCT 2026 | Thursday
Senores Pharmaceuticals confirms Rs 95.004 crore preferential issue use per exchange filings
29 OCT 2026 | Thursday
Senores Pharmaceuticals confirms proper use of Rs 500 crore IPO proceeds, CARE Ratings monitors
13 OCT 2026 | Tuesday
Senores Pharmaceuticals re-appoints Swapnil Shah as Managing Director for three years
13 OCT 2026 | Tuesday
Senores Pharmaceuticals re-appoints Swapnil Shah and Chetan Shah for three years
08 OCT 2026 | Thursday
Senores Pharmaceuticals confirms regulatory compliance for quarter ended September 30, 2026
24 SEPT 2026 | Thursday
Senores Pharmaceuticals will restrict trading for insiders during financial results announcement period
26 AUG 2026 | Wednesday
Senores Pharmaceuticals expands internationally with subsidiaries in Mexico and Canada
26 AUG 2026 | Wednesday
Senores Pharmaceuticals to establish subsidiaries in Mexico and Canada for distribution
26 AUG 2026 | Wednesday
Senores Pharmaceuticals appoints Dr. Shah as Director and approves ESOS 2026 for employees
26 AUG 2026 | Wednesday
Senores Pharmaceuticals appoints Dr. Shah, plans subsidiaries in Mexico and Canada

2026

Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced

Frequently asked questions

The share price of Senores Pharmaceuticals Ltd is ₹1,090.80 as of 20 Nov 2026 at 15:57.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now